Atherosclerosis: Cell biology and lipoproteins-paraoxonases protect against atherosclerosis and diabetes development

Current Opinion in Lipidology

Volumn 23, Issue 2, 2012, Pages 169-171

  Aviram, Michalel ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FOSTAMATINIB; LIPOPROTEIN; POMEGRANATE EXTRACT;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY ATHEROSCLEROSIS; CYTOLOGY; DIABETES MELLITUS; DISEASE COURSE; EDITORIAL; ENZYME ACTIVITY; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CELL BIOLOGY; DIABETES MELLITUS; HUMANS; LIPOPROTEINS; OXIDATIVE STRESS;

EID: 84858757313     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283513594     Document Type: Editorial

References (13)

1. Yla-herttuala S, Bentzon JF, Daemen M, et al. Stabilization of atherosclerotic plaques: position paper of the European Society of Cardiology (ESC) working group on atherosclerosis and vascular biology. Thromb Haemost 2011; 106:1-19.
2. Hirata Y, Tabata M, Kurobe H, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011; 58:248-255.
3. Hilgendrof I, Eisele S, Remer I, et al. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31:1991-1999.
4. Ta NN, Schuyler CA, Li YC, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58:157-166.
5. Duner P, To F, Beckmann K, et al. Immunization of apoE mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis. Cardiovasc Res 2011; 91:528-536.
6. Yu M, Romer KA, Nieland TJF, et al. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. Proc Natl Acad Sci USA 2011; 108:12243-12248.
7. Berry EM, Arnoni Y, Aviram M. The middle eastern & biblical origins of the Mediterranean diet. Public Health Nutr 2011; 14:2288-2295.
8. Balbir-Gurman A, Fuhrman B, Braun-Moscovici Y, et al. Consumption of pomegranate decreases serum oxidative stress and reduces disease activity in patients with active rheumatoid arthritis: a pilot study. Isr Med Assoc J (IMAJ) 2011; 13:474-479.
9. Connelly PW, Picardo CM, Potter PM, et al. Mouse serum paraoxonase-1 lactonase activity is specific for medium-chain length fatty acid lactones. Biochem Biophys Acta 2010; 181:39-45.
10. Koren-Gluzer M, Aviram M, Meilin E, et al. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates bcell insulin release. Atherosclerosis 2011; 19:510-518.
11. Kappelle PJ, de Boer JF, Perton FG, et al. Increased LCAT and hyperglycaemia decrease the antioxidative functionality of HDL. Eur J Clin Invest 2011. doi: 10.1111/j.1365-2362.2011.02604.x [Epub ahead of print]
12. Tavori H, Aviram M, Khatib S, et al. Paraoxonase1 protects macrophages from atherogenicity of a specific triglyceride isolated from human carotid lesion. Free Radic Biol Med 2011; 51:234-242.
13. Rosenblat M, Volkova N, Ward J, et al. Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Atherosclerosis 2011; 219: 49-56.